ROSTELATO, M.E.C.M.MATTOS, F.R.ZEITUNI, C.A.SOUZA, C.D.MOURA, J.A.MOURA, E.S.FEHER, A.COSTA, O.L.PELEIAS JUNIOR, F.S.MARQUES, J.R.O.BELFORT NETO, R.DUDALA, JOANNASTEGOWSKI, ZDZISLAW2022-10-272022-10-27ROSTELATO, M.E.C.M.; MATTOS, F.R.; ZEITUNI, C.A.; SOUZA, C.D.; MOURA, J.A.; MOURA, E.S.; FEHER, A.; COSTA, O.L.; PELEIAS JUNIOR, F.S.; MARQUES, J.R.O.; BELFORT NETO, R. Iridium-192 seed development for ophthalmic cancer treatment. In: DUDALA, JOANNA (ed.); STEGOWSKI, ZDZISLAW (ed.). In: INTERNATIONAL CONFERENCE ON DEVELOPMENT AND APPLICATIONS OF NUCLEAR TECHNOLOGIES, September 11-14, 2011, Krakow, Poland. <b>Abstract...</b> Krakow, Poland: Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, 2011. p. 144-144. Disponível em: http://repositorio.ipen.br/handle/123456789/33339.http://repositorio.ipen.br/handle/123456789/33339Considered a public health problem in Brazil, cancer is the second leading cause of mortality by disease, representing 13.2% of all deaths in the country [1]. Ophthalmic brachytherapy involves inserting an acrylic plate with radioactive material in the eyes of a patient for treatment of ocular tumors. This work is a partnership between Escola Paulista de Medicina - UNIFESP and the Instituto de Pesquisas Energéticas e Nucleares - IPEN for development and implementation of a cheaper therapeutic treatment for ophthalmic cancer with a iridium-192 source, to attend a greater number of patients. Iridium-192 is produced in nuclear reactor. It has a half-life of 74.2 days and decays by beta emission with average energy of 370 keV.[2,3]. The seed will be a platinum-iridium alloy core (80/20), encapsulated in a titanium tube [4]. This project will be divided into the following steps: characterization of materials by FRX (X-ray fluorescence) e EDS (Energy Dispersive Spectroscopy); iridium irradiation in the nuclear reactor IEA-R1; sealing of iridium-192 seed; leakage tests of iridium-192 source in accordance with standard ISO-9978 (radiation protection- Sealed radioactive sources- Leakage test methods) [5]; metallographic tests and measure the activity of the source. The evaluation for use in the ophthalmic treatment of cancer will be made later.144-144openAccessexternal irradiationeyesiridium 192neoplasmsradiotherapyseedstherapyResumo de eventos científicos0000-0001-5989-72870000-0002-7303-67200000-0003-2943-6097https://orcid.org/0000-0002-5054-0799http://orcid.org/0000-0003-1335-8864https://orcid.org/0000-0002-7303-6720https://orcid.org/0000-0003-2943-6097